Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Homodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling.

Lewis BC, Mackenzie PI, Miners JO.

Biochem Pharmacol. 2011 Dec 15;82(12):2016-23. doi: 10.1016/j.bcp.2011.09.007. Epub 2011 Sep 14.

PMID:
21930117
2.

3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7).

Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, Bélanger A.

Drug Metab Dispos. 2000 May;28(5):497-502.

3.

Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.

Innocenti F, Iyer L, Ramírez J, Green MD, Ratain MJ.

Drug Metab Dispos. 2001 May;29(5):686-92.

4.

Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10.

Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, Miners JO.

Drug Metab Dispos. 2009 Sep;37(9):1948-55. doi: 10.1124/dmd.109.028225. Epub 2009 Jun 1.

5.

Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation.

Lewis BC, Mackenzie PI, Elliot DJ, Burchell B, Bhasker CR, Miners JO.

Biochem Pharmacol. 2007 May 1;73(9):1463-73. Epub 2006 Dec 22.

PMID:
17223084
6.

Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction.

Takeda S, Ishii Y, Iwanaga M, Nurrochmad A, Ito Y, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H.

Mol Pharmacol. 2009 Apr;75(4):956-64. doi: 10.1124/mol.108.052001. Epub 2009 Jan 21.

7.

Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites.

Uchaipichat V, Galetin A, Houston JB, Mackenzie PI, Williams JA, Miners JO.

Mol Pharmacol. 2008 Oct;74(4):1152-62. doi: 10.1124/mol.108.048645. Epub 2008 Jul 22.

8.

Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4.

Takeda S, Ishii Y, Iwanaga M, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H.

Mol Pharmacol. 2005 Mar;67(3):665-72. Epub 2004 Dec 20.

9.

Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.

Gaganis P, Miners JO, Knights KM.

Biochem Pharmacol. 2007 May 15;73(10):1683-91. Epub 2007 Jan 28.

PMID:
17343829
10.

Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.

Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO.

Drug Metab Dispos. 2003 Sep;31(9):1086-9. Erratum in: Drug Metab Dispos. 2003 Dec;31(12):1541.

11.

Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity.

Yuan L, Qian S, Xiao Y, Sun H, Zeng S.

Biochem Pharmacol. 2015 May 1;95(1):58-70. doi: 10.1016/j.bcp.2015.03.002. Epub 2015 Mar 12.

PMID:
25770680
12.

Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol.

Chen M, LeDuc B, Kerr S, Howe D, Williams DA.

Drug Metab Dispos. 2010 Mar;38(3):368-75. doi: 10.1124/dmd.109.029900. Epub 2009 Dec 11.

13.

Human UGT2B7 catalyzes morphine glucuronidation.

Coffman BL, Rios GR, King CD, Tephly TR.

Drug Metab Dispos. 1997 Jan;25(1):1-4.

15.

Human UDP-glucuronosyltransferase 2B7.

Radominska-Pandya A, Little JM, Czernik PJ.

Curr Drug Metab. 2001 Sep;2(3):283-98.

PMID:
11513331
17.

Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10.

Kaivosaari S, Toivonen P, Hesse LM, Koskinen M, Court MH, Finel M.

Mol Pharmacol. 2007 Sep;72(3):761-8. Epub 2007 Jun 18.

18.

N-glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes.

Barbier O, Girard C, Breton R, Bélanger A, Hum DW.

Biochemistry. 2000 Sep 26;39(38):11540-52.

PMID:
10995221
19.

Cloning and characterisation of the first drug-metabolising canine UDP-glucuronosyltransferase of the 2B subfamily.

Soars MG, Fettes M, O'Sullivan AC, Riley RJ, Ethell BT, Burchell B.

Biochem Pharmacol. 2003 Apr 15;65(8):1251-9.

PMID:
12694866
20.

Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation.

Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, Miners JO.

J Pharmacol Exp Ther. 2007 Apr;321(1):137-47. Epub 2007 Jan 19.

Supplemental Content

Support Center